Glucagon

FOXA2’s Role in Glucose Regulation: New Review Highlights

by

FOXA2 serves as a master transcription factor that coordinates pancreatic development, maintains islet cell identity, and regulates systemic glucose homeostasis, according to a review published in the journal Genes & Diseases (DOI: 10.1016/j.gendis.2025.101972). By orchestrating gene networks from early organogenesis into adulthood, FOXA2 ensures the functional integrity of insulin-producing β-cells and glucagon-secreting α-cells, providing a … Read more

How Liraglutide Briefly Rewires Gut Microbiome: Mouse Study Findings

by

Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), triggers rapid but largely reversible shifts in the gut microbiome of obese mice, according to a study published in the journal Microbiology Spectrum. Researchers found that while the drug alters bacterial community structure during active treatment, these changes largely normalize within seven days of discontinuing the medication. … Read more

GLP-1 Receptor Activation Linked to Reduced Depression, Bipolar Disorder Risk

by

Genetic Insights into GLP-1R and Mental Health Genetic evidence suggests that lifelong activation of the glucagon-like peptide-1 receptor (GLP-1R) may reduce risks of major depressive disorder (MDD) and bipolar disorder (BD), according to a study published in Translational Psychiatry. Researchers used Mendelian randomization (MR) to analyze data from genome-wide association studies (GWASs), linking genetic variants … Read more

Semaglutide: Does Dose Impact Heart Health More Than Weight Loss?

by

New research suggests that the cardiovascular health benefits of semaglutide may be more closely tied to the drug’s dosage than to the amount of weight a patient loses. A retrospective study published in npj Cardiovascular Health found that patients reaching higher maximum doses of semaglutide—1.7 mg or greater—experienced significantly lower risks of heart failure, cerebrovascular … Read more

GLP-1 Drugs in Pregnancy: Do They Increase Birth Defect Risk?

by

A systematic review published in Scientific Reports found no statistically significant increase in major congenital malformations, stillbirths, or preterm births following maternal exposure to GLP-1 receptor agonists. While the data offers “cautious reassurance” for inadvertent exposure, researchers state the evidence certainty remains low, meaning these medications are not yet considered safe for routine use during … Read more

Can GLP-1 Drugs Help Prevent Breast Cancer? New Study Findings

by

A New Frontier in Cancer Prevention: Could Weight-Loss Drugs Change the Game? For decades, the medical community has searched for pharmacological ways to lower breast cancer risk beyond traditional hormone-blocking therapies. Now, a compelling new study published in JCO Oncology Practice suggests that the next breakthrough in cancer prevention might already be sitting in our … Read more

Daily orforglipron treatment reduces weight and blood sugar in seniors

by

The Shift Toward Oral Metabolic Health: A New Era for Seniors For years, the conversation around weight management in older adults has been cautious. The fear of muscle loss, the complexity of injectable medications, and a general lack of clinical data specifically targeting the 65+ demographic often left healthcare providers and patients hesitant. However, a … Read more

People judge weight loss more harshly when GLP-1 drugs are involved, study finds

by

The “Effort Gap”: Why Weight Loss Meds Trigger Social Backlash For decades, the narrative around weight loss has been centered on willpower. The prevailing belief is that the harder someone works—the more sweat and sacrifice they endure—the more they “deserve” their success. What we have is known as effort moralization: the psychological tendency to equate … Read more

GLP-1 drugs cut heart and kidney risks in type 1 diabetes study

by

GLP-1s: A Recent Chapter in Type 1 Diabetes Management? A groundbreaking analysis suggests glucagon-like peptide-1 receptor agonists (GLP-1RAs) – already well-established in type 2 diabetes treatment – could offer significant benefits for individuals living with type 1 diabetes (T1D). The research, published in Nature Medicine, points to reduced risks of cardiovascular events and kidney disease … Read more

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

by

The Future of Metabolic Health: Beyond GLP-1, Towards Comprehensive Solutions A landmark review published in The Lancet confirms what many clinicians are witnessing: modern incretin-based drugs are fundamentally changing how we approach obesity, type 2 diabetes (T2D), and related health issues. But the story doesn’t end with semaglutide and tirzepatide. The research points towards a … Read more

© 2026 Newsy Today. All rights reserved.


For contact, advertising, copyright, issues email: [email protected]

For contact, advertising, copyright, issues email: [email protected]